The antitumor agent imexon activates antioxidant gene expression: Evidence for an oxidative stress response

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3388-3394

  Baker, Amanda F ^a   Landowski, Terry ^a   Dorr, Robert ^a   Tate, Wendy R ^a   Gard, Jaime M C ^a   Tavenner, Breonna E ^a   Dragovich, Tomislov ^a   Coon, Amy ^a   Powis, Garth ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; COMPLEMENTARY DNA; IMEXON; NUCLEAR FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUND;

ADULT; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA BINDING; DNA MICROARRAY; EX VIVO STUDY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE; GENE EXPRESSION; GENE SEQUENCE; GLUTAREDOXIN 2 GENE; HUMAN; HUMAN CELL; MYELOMA CELL; OVARY ADENOCARCINOMA; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PEROXIREDOXIN 3 GENE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THIOREDOXIN REDUCTASE 1 GENE; UPREGULATION; WESTERN BLOTTING;

ANTIOXIDANTS; CELL LINE, TUMOR; CLINICAL TRIALS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HEXANONES; HUMANS; LEUKOCYTES, MONONUCLEAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34250613899     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0873     Document Type: Article

References (47)

1. Salmon SE, Hersh EM. Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. J Natl Cancer Inst 1994;86:228-30.
2. Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 1992;84:1238-44.
3. Hersh EM, Grogan TM, Funk CY, Taylor CW. Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy. J Immunother 1993;13:77-83.
4. Sagaster P, Kokoschka EM, Kokron O, Micksche M. Antitumor activity of imexon. J Natl Cancer Inst 1995;87:935-6.
5. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT. Induction of mitochondrial changes in myeloma cells by imexon. Blood 2001;97: 3544-51.
6. Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines. Int J Gastrointest Cancer 2005;36:15-28.
7. Dvorakova K, Payne CM, Tome ME, et al. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 2000;60:749-58.
8. Dvorakova K, Payne CM, Tome ME, et al. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Mol CancerTher 2002;1: 185-95.
9. Meyer AJ, Hell R. Glutathione homeostasis and redox-regulation by sulfhydryl groups. Photosynth Res 2005;86:435-57.
10. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000;29:312-22.
11. Wood ZA, Schroder E, Robin HJ, Poole LB. Structure, mechanism, and regulation of peroxiredoxins. Trends Biochem Sci 2003;28:32-40.
12. Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004;337:1-13.
13. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
14. Ainbinder E, Bergelson S, Pinkus R, Daniel V. Regulatory mechanisms involved in activator-protein-1 (AP-1)-mediated activation of glutathione-S-transferasegene expression by chemical agents. Eur J Biochem 1997;243:49-57.
15. Bossy-Wetzel E, Bakiri L, Yaniv M. Induction of apoptosis by the transcription factor c-Jun. EMBO J 1997; 16:1695-709.
16. Dhakshinamoorthy S, Long DJ, Jaiswal AK. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr Top Cell Regul 2000;36:201-16.
17. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 2004;36:1199-207.
18. Venugopal R, Jaiswal AK. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998;17:3145-56.
19. Sankaranarayanan K, Jaiswal AK. Nrf3 negatively regulates antioxidant-response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. J Biol Chem 2004;279: 50810-7.
20. Kobayashi A, Kang MI, Watai Y, et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 2006;26:221-9.
21. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A 1996;93:14960-5.
22. Nguyen T, Huang HC, Pickett CB. Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J Biol Chem 2000;275:15466-73.
23. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236: 313-22.
24. Meuillet EJ, Ihle N, Baker AF, et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 2004;14:513-27.
25. Motohashi H, Yamamoto M. Nrf2-1 defines a physiologically important stress response mechanism. Trends Mol Med 2004;10:549-57.
26. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene 2003;22:2417-21.
27. Patenaude A, Ven Murthy MR, Mirault ME. Mitochondrial thioredoxin system: effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis. J Biol Chem 2004;279:27302-14.
28. Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 2003;1:682-9.
29. Lundberg M, Johansson C, Chandra J, et al. Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms. J Biol Chem 2001;276:26269-75.
30. Sakurai A, Nishimoto M, Himeno S, et al. Transcriptional regulation of thioredoxin reductase 1 expression by cadmiumin vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol 2005;203: 529-37.
31. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003;278:12029-38.
32. Dragovich T, Dragovich D, Mendelson M, et al. Phase I trial of imexon in patients with advanced solid tumors. J Clin Oncol 2005;23:3153.
33. Lapperre TS, Jimenez LA, Antonicelli F, et al. Apocynin increases glutathione synthesis and activates AP-1 in alveolar epithelial cells. FEBS Lett 1999;443: 235-9.
34. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene 2001;20: 2476-89.
35. Nishinaka T, Yabe-Nishimura C. Transcription factor Nrf2 regulates promoter activity of mouse aldose reductase (AKR1B3) gene. J Pharmacol Sci 2005;97: 43-51.
36. Klatt P, Molina EP, De Lacoba MG, et al . Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J 1999;13:1481-90.
37. Filosto M, Tonin P, Vattemi G, Savio C, Rizzuto N, Tomelleri G. Transcription factors c-Jun/activator protein-1 and nuclear factor-κB in oxidative stress response in mitochondrial diseases. Neuropathol Appl Neurobiol 2003;29:52-9.
38. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 2003;43:233-60.
39. Moinova HR, Mulcahy RT. Up-regulation of the human γ- glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem Biophys Res Commun 1999;261:661-8.
40. Kim YC, Yamaguchi Y, Kondo N, Masutani H, Yodoi J. Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene 2003;22:1860-5.
41. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 2003;278: 8135-45.
42. Hayes JD, Chanas SA, Henderson CJ, et al. The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole, and ethoxyquin. Biochem Soc Trans 2000;28:33-41.
43. Kovacic P, Osuna JA, Jr. Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr Pharm Des 2000;6:277-309.
44. Lecane PS, Karaman MW, Sirisawad M, et al. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 2005;65:11676-88.
45. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002;62:5196-203.
46. Cheng GC, Schulze PC, Lee RT, Sylvan J, Zetter BR, Huang H. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp Cell Res 2004;300:297-307.
47. Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. Antioxidants enhance mammalian proteasome expression through the Keap1-2 signaling pathway. Mol Cell Biol 2003;23:8786-94.